IndustryCompany release

Psyence Biomedical reports $1.94M half-year loss as equity line lifts cash to $21.1M

Psyence Biomedical Ltd. (PBM) · Thu 19 Nov 2026

The Nasdaq-listed psychedelic medicines developer ended September 2026 with about $21.1M in cash, up from $7.4M in March, helped by equity line proceeds.

Psyence Biomedical, a Nasdaq-listed developer of botanical psilocybin and ibogaine medicines, has published unaudited interim financial statements for the six months ended 30 September 2026. The statements were authorised on 19 November 2026.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Psyence Biomedical Ltd. ↗

Article written by VigiEye from the official source (Psyence Biomedical Ltd.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →